Home > Transparency Posts > For Further Discussion — Comment from the Public About Transparency #2

For Further Discussion — Comment from the Public About Transparency #2

The views and opinions expressed in this comment are those of the author only and should not be regarded as those of the Transparency Task Force or FDA. The comment is posted by the Transparency Task Force simply to facilitate discussion.

 

My recommendation relates to cases where FDA does not approve one of the indications requested in a New Drug Application (NDA) or does not approve an indication requested in a Supplemental New Drug Application.  In such cases, FDA should make public the “non-approval letter” explaining why the indication was not approved, the relevant analysis by FDA’s medical officer and all clinical trials that were the basis for FDA’s non-approval. When a drug is marketed for at least one approved indication, it is foreseeable it will also be prescribed off-label for related indications, especially in cases where approval of the off-label indication has been sought.  A recent example with negative public health implications was Bextra® (valdecoxib), a drug withdrawn from the market for safety reasons.

 

As a Senior Assistant Attorney General in the Consumer Protection section of the Oregon Department of Justice, I led an investigation by a coalition of 34 State Attorneys General regarding the off-label promotion of Bextra to treat acute and perioperative pain.  This matter was resolved with a Stipulated General Judgment filed in Marion County Circuit Court.  In our Complaint we alleged, among other things, that after FDA refused to approve an application to market Bextra for acute and perioperative pain, the drug company went ahead and promoted these indications by distributing hundreds of thousands of copies of a positive study from the NDA without discussing or presenting a negative study from the NDA that was the basis for FDA’s refusal to approve.  Had FDA made public the non-approval letter, the analysis by the FDA medical officer assigned to review the NDA, and the relevant clinical trials, it would have been more difficult, if not impossible, to promote the drug off-label for these indications.

 

David Hart

Sr. Assistant Attorney General

Oregon Department of Justice

Civil Enforcement Division

  1. July 29, 2009 at 4:37 pm

    Thank you for your work on this important issue. Information is like air and water, people should have access to as much as they need.

  2. TSC
    July 30, 2009 at 9:02 am

    Simply put, the disclosure rules ought to be the same for both approved and rejected applications. Does the existing law compel the agency to give preferential non-disclosure treatment to the rejected applications? — I doubt that.
    I applaud the FDA for already taking steps in the right direction. The case in point is the new drug application for asenapine. Although the overall conclusion of the FDA review appears to be positive, there has been a conflict among reviewers regarding safety and efficacy of asenapine. The FDA made the right decision to convene the advisory committee and to make public all 1000 pages of supporting documentation here http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PsychopharmacologicDrugsAdvisoryCommittee/UCM173877.pdf . Now, the outside experts can see both sides of the issue and make their own recommendations, no matter whether the drug will be approved or rejected. Way to go, guys!

  3. sulumits retsambew
    August 5, 2009 at 10:13 pm

    Pretty good post. I just stumbled upon your blog and wanted to say that I have really enjoyed reading your blog posts.

  4. Kevin
    August 11, 2009 at 11:13 am

    FDA cops a lot of flack generally. There will always be those of extreme views anyway, but the move to more transparency is definitely a step in the right direction. I fully support what is happening in this regard.

  5. puppy playpen
    December 28, 2009 at 7:22 am

    I’ve never even realised how much is quietly kept back from us until recently all i can say is ime glad there are people working on it, after all whey shouldn’t we be kept in the loop with the amount of taxes we pay.

  6. lig tv izle
    January 13, 2010 at 6:40 am

    FDA cops a lot of flack generally

    • скачать на nokia мелодии
      October 18, 2013 at 12:18 pm

      Howdy. I ran across your web site use of live messenger. That is certainly a very well published article. We are guaranteed to save that obtainable here we are at find out more of your handy information. Wanted write-up. I’m going to definitely come back.

    • natural male enhancement
      December 22, 2013 at 10:22 am

      Ѕweet blog! I found it while surfing arounԁ onn Yahoo News.
      Do you have any tipѕ on how to get listed in Yahoo News?
      I’ve been trying for a while but I never seem
      to get there! Thanks

  7. Gino Siller
    January 29, 2010 at 4:22 pm

    Thank you David for posting this. I do think that the FDA should of made public the non-approval letter.

  8. Alessandro
    March 13, 2010 at 10:24 am

    Really amazing site and full of good informations..
    We are Türkei Reisen from Germany near Stuttgart and we think that this site ist very interesting and amazing. Sorry for our English :)
    Good luck and many Greetings from Germany/Stuttgart
    Ale

  9. Frank P
    March 31, 2010 at 9:55 am

    I agree with a lot of the comments here – access to information is extremely important so people can make informed choices.

  10. jordan retro v
    May 14, 2010 at 9:30 pm

    I agree with a lot of the comments here – access to information is extremely important so people can make informed choices.

  11. Dustin Davis
    July 27, 2010 at 10:52 am

    I agree. The FDA works for the people. If they do a study, their findings should be made public for all. Thanks for your work on this.

  12. Bella Simpson
    December 2, 2010 at 5:35 pm

    Impressive post. Waiting for you to continue the topic.

    Bella Simpson
    escort agency warsaw

  13. Avril Kuree
    December 3, 2010 at 5:50 pm

    Great post. Waiting for you to continue the topic.

    Avril Kuree
    north west london escorts

  14. Hilary Simpson
    February 22, 2011 at 7:34 pm

    It was certainly interesting for me to read this blog. Thank you for it. I like such topics and everything that is connected to this matter. I would like to read more on that blog soon.

    Hilary Simpson

  15. jual gorden murah
    March 31, 2014 at 7:40 am

    I know this if off topic but I’m looking into starting my own blog
    and was wondering what all is needed to get
    setup? I’m assuming having a blog like yours would cost a pretty penny?
    I’m not very web smart so I’m not 100% certain.
    Any recommendations or advice would be greatly appreciated.
    Kudos

  1. No trackbacks yet.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

Follow

Get every new post delivered to your Inbox.

Join 174 other followers

%d bloggers like this: